Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article summarizing a study that evaluated lung function decline after taking anti-fibrotic therapy for IPF patients. Lung function decline, as measured by forced vital capacity (FVC), can help predict survival in patients with IPF, particularly among those prescribed the anti-fibrotic therapies for IPF.

Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com